Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 668 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mild Alzheimer Disease Clear all
Recruiting Phase 2 Interventional

Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)

NCT05565833
View directory record Official record
Conditions
Insomnia, Cognitive Dysfunction, Mild Cognitive Impairment, Sleep Initiation and Maintenance Disorders, Sleep Disorders, Intrinsic, Dyssomnias, Sleep Wake Disorders, Nervous System Diseases, Alzheimer Disease
Interventions
SHUTi OASIS, Patient Education
Behavioral · Other
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

SNIFF - Combo INI+EMPA Trial

NCT05081219
View directory record Official record
Conditions
Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease
Interventions
Insulin (Humulin® R U-100), Empagliflozin 10 MG, Aptar Pharma CPS Intranasal Delivery Device, Placebo (Insulin Diluent), Placebo (Capsules)
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Not applicable Interventional Results available

Hearing Aid and Individuals With Cognitive Disorders

NCT04049643
View directory record Official record
Conditions
Presbycusis, Bilateral, Alzheimer Disease 2 Due to Apoe4 Isoform, Mild Cognitive Impairment
Interventions
Audiologist-based fitting, Service-only Fitting, Device-only fitting
Device
Lead sponsor
Yu-Hsiang Wu
Other
Eligibility
55 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Not applicable Interventional Results available

Stimulation to Improve Memory

NCT03875326
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia of Alzheimer Type
Interventions
1 mA HD-tDCS, 2 mA HD-tDCS, 3 mA HD-tDCS, Sham
Device
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

NCT04070378
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Daratumumab Injection
Drug
Lead sponsor
Marc L Gordon, MD
Other
Eligibility
55 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Not applicable Interventional Results available

Decision Making and Implementation of Aging-in-Place/Long Term Care Plans Among Older Adults

NCT03960476
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Long-Term Care Planning
Interventions
PlanYourLifespan.org
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
55 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)

NCT00438568
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Regular Insulin, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
55 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Jul 21, 2026, 9:51 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

NCT06548191
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Alzheimer's Disease
Interventions
Time-restricted eating
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 21, 2026, 9:51 AM EDT
Active, not recruiting Phase 2 Interventional

Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

NCT04784416
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Active tPBM-2.0, Sham tPBM-2.0, 18F-MK-6240
Device · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years to 85 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Jul 21, 2026, 9:51 AM EDT
Completed No phase listed Observational

Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)

NCT05364307
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Prescreener database
Other
Lead sponsor
Global Alzheimer's Platform Foundation
Other
Eligibility
50 Years to 90 Years
Enrollment
1,555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
San Diego, California • Santa Ana, California • Aventura, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Results available

A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease

NCT00988598
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Glendale, California • Gainesville, Florida • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Jul 21, 2026, 9:51 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

NCT07012993
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Healthy Volunteers
Interventions
18F-Florbetapir or 18F-Flutemetamol
Drug
Lead sponsor
Akiva Mintz
Other
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 9:51 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

NCT00555204
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-089, placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
55 Years to 90 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
42
States / cities
Phoenix, Arizona • Sun City, Arizona • Fresno, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Jul 21, 2026, 9:51 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Study to Understand Novel Biomarkers in Researching Dementia

NCT06547099
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Clinical tau PET, Clinical amyloid test, Research blood collection, Cognitive assessments
Diagnostic Test · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jul 21, 2026, 9:51 AM EDT
Recruiting Not applicable Interventional

Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease

NCT06484244
View directory record Official record
Conditions
Alzheimers Disease, Mild Cognitive Impairment
Interventions
5 Sessions of Split-belt Treadmill-based Locomotor Adaptation
Other
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 21, 2026, 9:51 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD

NCT05881239
View directory record Official record
Conditions
Subjective Cognitive Concerns, Mild Cognitive Impairment, Mild Behavioral Impairment, Healthy Aging
Interventions
AROMHA Brain Health Test
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease

NCT01254773
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Experimental Bapineuzumab
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 89 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
28
States / cities
Tucson, Arizona • La Habra, California • Lomita, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Not applicable Interventional Results available

Self-Administered Interactive Exercise Program (Tele-Exergame)

NCT07072962
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Mild Alzheimer Disease, Memory Deficits
Interventions
home-based self-administered interactive exercise
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Jul 21, 2026, 9:51 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

TMS in Preclinical and Prodromal AD: Modulation of Brain Networks and Memory

NCT04294888
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Aging
Interventions
repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)

NCT01595646
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Saline, Insulin detemir, Insulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 89 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Jul 21, 2026, 9:51 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

NCT04592341
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Gantenerumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Atlantis, Florida • Maitland, Florida • Ocala, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study

NCT02585934
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RVT-101, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
61
States / cities
Phoenix, Arizona • Tucson, Arizona • Encino, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Strengthening Exercise on the Brain for Early Dementia and Normative Older Adults

NCT01264614
View directory record Official record
Conditions
Cognitive Decline, Dementia, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Strengthening exercise
Behavioral
Lead sponsor
Union College, New York
Other
Eligibility
55 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Jul 21, 2026, 9:51 AM EDT
Recruiting Not applicable Interventional

Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease

NCT05795634
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Trier Social Stress Test
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 21, 2026, 9:51 AM EDT